Xeris Biopharma Holdings Inc (XERS) (Q3 2026) Earnings Call Highlights: Revenue Surges 44% as ... - Yahoo Finance
Xeris's third-quarter total revenue rose 44% year over year to $107.2 million, while net product revenue increased 43% to $106.3 million. [[fact-at9a5g8ny]] Recorlev net revenue grew 93% year over year to $71.5 million. [[fact-7ob9hspxc]] Adjusted EBITDA improved 77% year over year to $30.8 million, and net income was $11.3 million versus $0.6 million a year earlier. [[fact-99jhskk52]] The company raised full-year 2026 revenue guidance to $395 million-$405 million and increased its 2030 revenue outlook from $750 million to more than $1 billion. [[fact-y1hm8ixxl]] G-Voq net revenue fell year over year to $21.7 million from $25.2 million, which the company attributed to a one-time $4 million gross-to-net adjustment in the Medicaid channel. [[fact-6m4wnh6p0]]
Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript
Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript(摘要待生成)
Xeris Biopharma: Q3 Earnings Snapshot - Yahoo Finance
Xeris Biopharma: Q3 Earnings Snapshot - Yahoo Finance(摘要待生成)
Xeris Biopharma, 8-K (2.02, 9.01): reported results of operations
Xeris Biopharma reported third-quarter 2026 revenue of $107.2 million, up 44% year over year, and net income of $11.3 million; it raised 2026 revenue guidance to $395 million–$405 million and its 2030 outlook to more than $1 billion.
Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs
Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs TradingView
Xeris Biopharma, 8-K (5.02, 7.01, 9.01): director or officer change
Xeris Biopharma appointed Menassie M. Taddese to its Board of Directors, effective November 2, 2026, and named him to the Audit Committee.